Breaking Finance News

A report released today by Evercore ISI about BioMarin Pharm (NASDAQ:BMRN) raises the target price to $100.00

In a report released on Thursday August 17, 2017 Evercore ISI increased the stock price target of BioMarin Pharm (NASDAQ:BMRN) to $100.00 reporting a possible upside of 0.20%.

Yesterday BioMarin Pharm (NASDAQ:BMRN) traded -1.70% lower at $83.07. BMRN’s 50-day average is $88.18 and its two hundred day average is $89.98. With the last stock price close down -9.25% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.05% over the same period. Trade Volume was down over the average, with 251,658 shares of BMRN changing hands under the typical 1,295,670

Performance Chart

BioMarin Pharm (NASDAQ:BMRN)

With a total market value of $0, BioMarin Pharm has 52 week low of $78.42 and a 52 week high of $102.06 .

In addition to Evercore ISI reporting its stock price target, a total of 20 brokers have issued a research note on the company. The average stock price target is $116.10 with 6 brokers rating the stock a strong buy, 11 brokers rating the stock a buy, 2 brokers rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About BioMarin Pharm (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.